SubsidieMeestersRebuilding Joint Surface to Prevent Pain and Immobility
Askel's COPLA® implant promotes cartilage regeneration and quick rehabilitation to prevent osteoarthritis, aiming to establish a gold standard for pain-free joint movement and improved quality of life.
Projectdetails
Introduction
A healthy layer of articular cartilage at the end of bones in joints is essential for painless movement. When cartilage is damaged, it has minimal innate regenerative properties and there is no effective medical cure.
Impact of Cartilage Damage
Cartilage damage seriously reduces quality of life and has severe economic impact since loss of cartilage leads to osteoarthritis (OA) that causes hundreds of billions of Euros in healthcare and related costs annually.
Challenges in Cartilage Restoration
Many attempts have been made to restore joint surface cartilage, but the tissue has shown to be extremely difficult to rebuild.
Innovative Solution
Askel has developed a unique way to rebuild joint surfaces for pain-free movement. COPLA® is a biodegradable implant that creates a weight-adaptive microenvironment in the damaged site, enabling quick rehabilitation and cartilage regeneration to prevent OA.
Future Outlook
COPLA® will become the Gold Standard for early cartilage repair with rapid recovery and long-term results, ensuring pain-free movement, high quality of life, and prevention of OA.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.000 |
| Totale projectbegroting | € 3.570.000 |
Tijdlijn
| Startdatum | 1-1-2022 |
| Einddatum | 30-6-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- ASKEL HEALTHCARE OYpenvoerder
Land(en)
Geen landeninformatie beschikbaar
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Development of a Complete Triple Action Injectable Treatment for OsteoarthritisRelevium Ltd aims to validate and commercialize Hydrobloc, a unique therapy that regenerates cartilage, alleviates pain, and improves joint function in osteoarthritis patients. | EIC Transition | € 2.398.115 | 2022 | Details |
Regulation of Articular Cartilage Zonal Emergence: Harnessing Developmental Pathways to Enhance RegenerationReZone aims to uncover the mechanisms of zonal emergence in articular cartilage using a goat model to enhance regeneration and improve treatment for cartilage injuries. | ERC COG | € 2.265.746 | 2024 | Details |
Restoring the structural collagen network in the regeneration of cartilageRe-COLL aims to develop durable implants for damaged joints by engineering anisotropic collagen networks through biofabrication and in vitro models, enhancing tissue regeneration and stability. | ERC ADG | € 2.500.000 | 2024 | Details |
SyCap MechanoAvalanche Medical ontwikkelt een innovatief kunststof mini-implantaat voor de behandeling van knie kraakbeendefecten bij middelbare leeftijdspatiënten, gericht op duurzaam functieherstel zonder gewrichtsvervanging. | MIT Haalbaarheid | € 20.000 | 2022 | Details |
Development of a Complete Triple Action Injectable Treatment for Osteoarthritis
Relevium Ltd aims to validate and commercialize Hydrobloc, a unique therapy that regenerates cartilage, alleviates pain, and improves joint function in osteoarthritis patients.
Regulation of Articular Cartilage Zonal Emergence: Harnessing Developmental Pathways to Enhance Regeneration
ReZone aims to uncover the mechanisms of zonal emergence in articular cartilage using a goat model to enhance regeneration and improve treatment for cartilage injuries.
Restoring the structural collagen network in the regeneration of cartilage
Re-COLL aims to develop durable implants for damaged joints by engineering anisotropic collagen networks through biofabrication and in vitro models, enhancing tissue regeneration and stability.
SyCap Mechano
Avalanche Medical ontwikkelt een innovatief kunststof mini-implantaat voor de behandeling van knie kraakbeendefecten bij middelbare leeftijdspatiënten, gericht op duurzaam functieherstel zonder gewrichtsvervanging.